Inhaltsverzeichnis
Auswahl der wissenschaftlichen Literatur zum Thema „Paraneoplastic neurological syndromes“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Paraneoplastic neurological syndromes" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Paraneoplastic neurological syndromes"
Pathirana, KD. „Paraneoplastic neurological syndromes“. Ceylon Medical Journal 53, Nr. 4 (26.01.2009): 148. http://dx.doi.org/10.4038/cmj.v53i4.290.
Der volle Inhalt der QuelleChad, David A., und Lawrence D. Recht. „Neurological Paraneoplastic Syndromes“. Cancer Investigation 6, Nr. 1 (Januar 1988): 67–82. http://dx.doi.org/10.3109/07357908809077030.
Der volle Inhalt der QuelleBashir, R., und F. Hochberg. „Paraneoplastic Neurological Syndromes“. Cancer Investigation 6, Nr. 1 (Januar 1988): 117–18. http://dx.doi.org/10.3109/07357908809077035.
Der volle Inhalt der QuelleNath, U., und R. Grant. „Neurological paraneoplastic syndromes.“ Journal of Clinical Pathology 50, Nr. 12 (01.12.1997): 975–80. http://dx.doi.org/10.1136/jcp.50.12.975.
Der volle Inhalt der QuelleSutton, Ian. „Paraneoplastic neurological syndromes“. Current Opinion in Neurology 15, Nr. 6 (Dezember 2002): 685–90. http://dx.doi.org/10.1097/00019052-200212000-00005.
Der volle Inhalt der QuelleSutton, Ian. „Paraneoplastic neurological syndromes“. Current Opinion in Neurology 15, Nr. 6 (Dezember 2002): 685–90. http://dx.doi.org/10.1097/01.wco.0000044764.39452.64.
Der volle Inhalt der QuelleLeypoldt, F., und K. P. Wandinger. „Paraneoplastic neurological syndromes“. Clinical & Experimental Immunology 175, Nr. 3 (04.02.2014): 336–48. http://dx.doi.org/10.1111/cei.12185.
Der volle Inhalt der QuelleDalmau, Josep O., und Jerome B. Posner. „Neurological Paraneoplastic Syndromes“. Neuroscientist 4, Nr. 6 (November 1998): 443–53. http://dx.doi.org/10.1177/107385849800400616.
Der volle Inhalt der QuelleSmitt, Peter Sillevis. „Paraneoplastic neurological syndromes“. Lancet Neurology 1, Nr. 7 (November 2002): 408. http://dx.doi.org/10.1016/s1474-4422(02)00218-1.
Der volle Inhalt der QuelleGraus, Francesc, und Josep Dalmau. „Paraneoplastic neurological syndromes“. Current Opinion in Neurology 25, Nr. 6 (Dezember 2012): 795–801. http://dx.doi.org/10.1097/wco.0b013e328359da15.
Der volle Inhalt der QuelleDissertationen zum Thema "Paraneoplastic neurological syndromes"
Villagrán-García, Macarena. „Clinical-immunological characterization and immune tolerance breakdown in paraneoplastic neurological syndromes associated with Hu antibodies“. Electronic Thesis or Diss., Lyon 1, 2024. http://www.theses.fr/2024LYO10259.
Der volle Inhalt der QuelleHu antibodies, the most common in paraneoplastic neurological syndromes (PNS), strongly indicate small-cell lung cancer (SCLC). The clinical spectrum of Hu-PNS is diverse, most patients develop multifocal central, peripheral, and/or autonomic nervous system dysfunction. Despite extensive research, questions remain, namely regarding the immunological basis of clinical heterogeneity and why only a minority of SCLC patients develop Hu-PNS. Our PhD project aims to phenotype Hu-PNS patients, explore the immunogenetics and humoral responses underlying neurological phenotypes, and the genomic and transcriptomic features of their SCLC. First, we described 466 Hu-PNS patients. Hierarchical clustering identified three groups: patients with central nervous system (CNS) involvement; isolated neuropathy; and mixed CNS/peripheral phenotypes. Overall survival was similar across groups, primarily determined by cancer, but dysautonomia, present in 26% of patients, significantly influenced neurological mortality. Prominent CNS dysfunction led to fatal cardiovascular dysautonomia or central hypoventilation, while peripheral involvement was associated with gastrointestinal or secretomotor alterations, without increased mortality risk. We also characterized patients who developed neurological syndromes with Hu antibodies after immune checkpoint inhibitor (ICI) treatment. These patients were clinically indistinguishable from spontaneous cases and shared a strong association with SCLC, suggesting ICIs may induce Hu-PNS. Second, we immunologically investigated neurological phenotypes using two approaches. HLA genotyping of 100 patients confirmed an association with the DR3~DQ2 haplotype, particularly in patients with sensory neuropathy, and absent in those with only CNS involvement. Phage immunoprecipitation sequencing was used to evaluate Hu antibody epitope reactivity and other autoantibodies in serum and/or CSF of 210 patients. We found no direct clinical association with the Hu dominant epitope, but epitope reactivity differed between serum and CSF in 75% of patients with paired samples. This variation correlated with sample timing and phenotype: CSF from patients with differing serum/CSF epitopes was collected later after PNS onset, while patients with serum/CSF consistent epitope reactivity always had CNS phenotypes. In addition, we identified reactivities to other proteins, some more specific to serum or CSF, and a subset linked to specific phenotypes. Third, we examined SCLC molecular features of Hu-, GABAbR-PNS and control patients. Next-generation sequencing, copy number variation analysis, and bulk-RNA sequencing revealed no mutations, gains, deletions, or overexpression in the Hu gene family of Hu-PNS SCLC. However, a distinct transcriptomic profile with upregulated genes largely related to immune system processes characterized these tumors. We also identified specific genes upregulated in the SCLC of patients with sensory neuropathy, some of which were linked to axonogenesis and neuropathy development. Our findings suggest multiple factors contribute to Hu-PNS clinical variability, particularly a broad range of additional autoantigens. These may be partly driven by gene expression patterns in SCLC, as some upregulated genes in patients with sensory neuropathy were linked to axonogenesis. Genetic predisposition may also favor specific phenotypes, as the DR3~DQ2 haplotype was associated with sensory neuropathy. Compartmentalization within the nervous system could further contribute, as most patients targeted different Hu epitopes in serum and CSF, and some autoantigens were more specific to CSF. Finally, Hu genes alterations in SCLC are unlikely causes of neoantigenicity, while a distinct immune-related gene profile and ICIs could contribute to immune tolerance breakdown. This work advances understanding of Hu-PNS complexity and paves the way for further studies into the immunological and molecular drivers of paraneoplastic immunity
Gebauer, Christina. „The Janus face of immunity : how anti-tumor immunity leads to autoimmunity in paraneoplastic neurological diseases“. Thesis, Toulouse 3, 2016. http://www.theses.fr/2016TOU30139/document.
Der volle Inhalt der QuelleParaneoplastic neurological disorders (PNDs) are rare human autoimmune diseases that mostly affect the central nervous system (CNS). They are triggered by an efficient immune response against a neural self-antigen that is ectopically expressed in neoplastic tumor cells and naturally expressed in CNS cells. Due to this shared antigenic expression, the immune system reacts not only to tumor cells but also to neural cells resulting in neurological damage. Growing data point to a major role of cell-mediated immunity in PNDs associated to autoantibodies against intracellular proteins. However, its precise contribution in the pathogenesis remains unclear. Two illustrative examples of possibly cell-mediated PNDs are the Hu-syndrome, characterized by inflammation and widespread los of neurons, and paraneoplastic cerebellar degeneration (PCD), characterized by the selective loss of Purkinje cells. PCD develops mostly in patients with gynecologic carcinomas that express the Purkinje neuron-specific CDR2 protein whereas most patients with the Hu-syndrome harbor small cell lung cancer expressing the neuron-specific protein HuD. In this context, our study aimed to investigate the impact of anti-tumor cellular immune responses in the development of these PNDs. To this end, we developed two animal models mimicking the Hu-syndrome and PCD. We used a tumor cell line expressing the hemagglutinin (HA) of influenza virus to induce an anti-tumor response in CamK-HA mice, which express HA in CNS neurons and L7-HA mice, which express HA only in cerebellar Purkinje neurons. To promote and track the T cell response against the HA antigen, naïve HA-specific CD8+ and/or CD4+ T cells, originating from TCR-transgenic animals, were transferred into these mice. We demonstrate that HA-expressing tumors, but not control tumors, induce in vivo activation, proliferation and differentiation of naïve HA-specific CD4+ and CD8+ T cells into effector cells. Moreover, the collaboration between these two T cell subsets was needed to control tumor growth and induce CNS inflammation in CamK-HA mice. In L7-HA mice the additional injection of the antibody against the inhibitory receptor CTLA-4 was necessary to allow T cells to enter the cerebellum to cause inflammation and the subsequent destruction of Purkinje neurons. Furthermore, in L7-HA mice we demonstrate that cytotoxic CD8+ T cells are the main effectors driving the disease. Thus, these two new mouse models provide further insights into the cellular mechanisms of PND whereby a potent anti-tumor immunity triggers a cancer-associated autoimmune disease, and may therefore help to develop new therapeutic strategies against PND
Sutton, Ian. „Investigation of cytotoxic T lymphocyte responses to the HuD and Yo antigens in individuals with paraneoplastic neurological syndromes“. Thesis, University of Birmingham, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.274426.
Der volle Inhalt der QuelleCouillault, Coline. „Hétérogénéité et mécanismes d’initiation de la réponse humorale dans les tumeurs du sein et de l’ovaire“. Thesis, Lyon, 2019. http://www.theses.fr/2019LYSE1051/document.
Der volle Inhalt der QuelleB and plasma cells are rising as crucial cells in the immune surveillance of tumors, even though their pro- or anti-tumor role is still debated. We argue that this dual functionality of B cells could depend on the identity of tumor-infiltrating B cell subsets and/or by the nature of the antibodies they produce. With that knowledge, we showed that breast and ovarian tumors are usually infiltrated by memory B cells and plasma cells that express and/or produce mainly IgG or IgA. This last class of Ig in highly enriched in in situ carcinomas of the breast, corresponding to earlier tumors, and in 15-20% of invasive tumors, suggesting a differential role of IgG and IgA in tumor progression. IgA, that can be monomeric or dimeric in tumors, often target antigens that differ from those targeted by IgG. We also show that antigens targeted by IgA and IgG in the tumor are often involved in functions related to the development of tissues and DNA interactions, and can be share amongst patients and between breast and ovarian tumors, suggesting their importance in the anti-tumor immune response. In parallel, using tumors from patients suffering from a paraneoplastic neurological syndrome, we established that the concomitant induction of IgG PC and CD8+ cytotoxic T cells in the tumor is associated wth amplifications and/or mutations in the genes of tumor antigens. These results highlight the importance of B cells and Ig in the anti-tumor immune response and give leads to look for new targets in immunotherapy
Bücher zum Thema "Paraneoplastic neurological syndromes"
Sutton, Ian John. Investigation of cytotoxic T lymphocyte responses to the HuD and Yo antigens in individuals with paraneoplastic neurological syndromes. Birmingham: University of Birmingham, 2003.
Den vollen Inhalt der Quelle findenJordan, Nerissa. Non-metastatic neurological manifestations of malignancy. Herausgegeben von Patrick Davey und David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0238.
Der volle Inhalt der QuelleCaraceni, Augusto, Cinzia Martini und Fabio Simonetti. Neurological problems in advanced cancer. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656097.003.0141.
Der volle Inhalt der QuelleBielekova, Bibiana, Gary Birnbaum und Robert P. Lisak, Hrsg. Neuroimmunology. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780190050801.001.0001.
Der volle Inhalt der QuelleCornblath, David R., und Richard A. C. Hughes. Peripheral neuropathy. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199658602.003.0013.
Der volle Inhalt der QuelleBuchteile zum Thema "Paraneoplastic neurological syndromes"
Vedeler, C. A., J. C. Antoine, B. Giometto, F. Graus, W. Grisold, J. Honnorat, P. A. E. Sillevis Smitt, J. J. G. M. Verschuuren und R. Voltz. „Paraneoplastic Neurological Syndromes“. In European Handbook of Neurological Management, 447–57. Oxford, UK: Wiley-Blackwell, 2010. http://dx.doi.org/10.1002/9781444328394.ch31.
Der volle Inhalt der QuelleRossiñol, Tomeu, und Francesc Graus. „Paraneoplastic Neurological Syndromes“. In Diagnostic Criteria in Autoimmune Diseases, 421–26. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-60327-285-8_77.
Der volle Inhalt der QuelleMuñiz-Castrillo, Sergio, und Jérôme Honnorat. „Paraneoplastic Neurological Syndromes“. In Neuroimmune Diseases, 439–85. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-19515-1_14.
Der volle Inhalt der QuelleZoccarato, Marco, Luigi Zuliani und Bruno Giometto. „Paraneoplastic Neurological Syndromes“. In Prognosis of Neurological Diseases, 355–61. Milano: Springer Milan, 2015. http://dx.doi.org/10.1007/978-88-470-5755-5_27.
Der volle Inhalt der QuelleLewerenz, Jan, und Frank Leypoldt. „Paraneoplastic Neurological Syndromes“. In Cerebrospinal Fluid in Clinical Neurology, 353–85. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-01225-4_21.
Der volle Inhalt der QuelleSpatola, Marianna. „Paraneoplastic Neurological Syndromes“. In Neuroimmunology, 243–60. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-61883-4_16.
Der volle Inhalt der QuelleDalmau, Josep, und Jerome B. Posner. „Neurological paraneoplastic syndromes“. In Immunoneurology, 203–13. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-61191-9_16.
Der volle Inhalt der QuelleMuñiz-Castrillo, Sergio, Macarena Villagrán-García und Jérôme Honnorat. „Paraneoplastic Neurological Syndromes“. In Neuroimmune Diseases, 1–48. Cham: Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-24297-7_14-1.
Der volle Inhalt der QuelleMuñiz-Castrillo, Sergio, Macarena Villagrán-García und Jérôme Honnorat. „Paraneoplastic Neurological Syndromes“. In Neuroimmune Diseases, 567–614. Cham: Springer Nature Switzerland, 2024. http://dx.doi.org/10.1007/978-3-031-60006-7_14.
Der volle Inhalt der QuelleRubin, Michael, Jason Broker und Thomas B. Toothaker. „Paraneoplastic Neurological Syndromes, Overview“. In Encyclopedia of Medical Immunology, 835–40. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-0-387-84828-0_5.
Der volle Inhalt der QuelleKonferenzberichte zum Thema "Paraneoplastic neurological syndromes"
Granger, Andre, Tina Rajnauth, Divyanshu Dubey, John Mills, Michelle Mauermann, Sarah Berini, P. James B. Dyck und Christopher Klein. „Peripheral Nerve Pathology in Antibody Positive Paraneoplastic Neurological Syndromes (P11-8.005)“. In 2023 Annual Meeting Abstracts. Lippincott Williams & Wilkins, 2023. http://dx.doi.org/10.1212/wnl.0000000000203395.
Der volle Inhalt der QuelleCaiza-Zambrano, Francisco, Fabio Gonzalez, Julio Galarza, Mauricio Benetti, Claudia Uribe Roca, Pablo Bonardo, Manuel Fernández Pardal, Luciana León Cejas und Ricardo Reisin. „Paraneoplastic Neurological Syndromes: A Single-Center Retrospective Study in Argentina (P9-13.005)“. In 2023 Annual Meeting Abstracts. Lippincott Williams & Wilkins, 2023. http://dx.doi.org/10.1212/wnl.0000000000202816.
Der volle Inhalt der QuellevanDuijn, Martijn M., Peter Maat, Lennard J. Dekker, Theo M. Luider und Peter A. Sillevis Smitt. „Abstract 1277: Antigen-specific markers for paraneoplastic neurological syndromes obtained by proteomic analysis of patient immunoglobulins“. In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-1277.
Der volle Inhalt der QuelleToledo, Zoe De, Sarah L. Smyth, Hooman Soleymani Majd, Zoe Traill, Kezia Gaitskell und Sarosh Irani. „121 Paraneoplastic neurological syndromes and the importance of prompt recognition to aid the diagnosis of underlying gynaecological malignancy“. In ESGO 2024 Congress Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/ijgc-2024-esgo.487.
Der volle Inhalt der QuelleFrille, A., S. Tegelkamp, M. Lerche, N. Linder, JJ Rumpf, S. Hesse und H. Wirtz. „Paraneoplastic neurologic syndromes in lung cancer“. In 21. Herbsttagung der Mitteldeutschen Gesellschaft für Pneumologie und Thoraxchirurgie. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0039-3401412.
Der volle Inhalt der QuellePuppalwar, S., und D. Turnbull. „An unusual case of paraneoplastic neurological syndrome“. In 17th Annual Conference of Indian Society of Neuroanaesthesiology and Critical Care. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0038-1667598.
Der volle Inhalt der QuelleCarvalho, Ana Cláudia Pires, Stella Angelis Trivellato, Guilherme Jardini Drumond Anastacio, Fernanda Rezende Dias, Luisa Crevelin Costa, Juliana Akita und Natália de Castro Fim Nakao. „Lambert-Eaton syndrome without an identified neoplasm“. In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.504.
Der volle Inhalt der QuelleTegelkamp, S., M. Lerche, H. Wirtz und A. Frille. „Systematic analysis of paraneoplastic neurologic syndromes in lung cancer patients“. In 60. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1678067.
Der volle Inhalt der QuelleCanzian, Kássia Braga, Marcella Canato Toloi, David Vargas Freitas Teixeira, Vanessa de Freitas Moreira, Amanda Freitas Alves, Eric Dupont, Fernanda Maria Gonçalves de Sousa Moura, Isabela de Almeida Stella, Thiago Ivan Vilchez Santillan und Herval Ribeiro Soares Neto. „Chronic paraneoplastic polyradiculoneuropathy during colorectal cancer: a case report“. In XIV Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2023. http://dx.doi.org/10.5327/1516-3180.141s1.633.
Der volle Inhalt der QuelleMorais, Gabriela Lopes de, Manoella Guerra de Albuquerque Bueno, Guilherme Otero Brum, Eder Leandro da Silva Dantas, Nathalia Rossoni Ronchi, Katharina Vieira Messias und Vanessa Daccach Marques. „Anti-hu neuropathy as a paraneoplastic syndrome: the pursuit for the primary site.“ In XIV Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2023. http://dx.doi.org/10.5327/1516-3180.141s1.418.
Der volle Inhalt der Quelle